Formulation development of a plant-derived H1N1 influenza vaccine containing purified recombinant hemagglutinin antigen

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 4, 2012, Pages 453-464

  Iyer, Vidyashankara ^a,b   Liyanage, Mangala Roshan ^a,d   Shoji, Yoko ^c   Chichester, Jessica A ^c   Jones, R Mark ^c   Yusibov, Vidadi ^c   Joshi, Sangeeta B ^a   Middaugh, C Russell ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b University of Kansas   (United States)

^c Fraunhofer USA Inc   (United States)

^d Dendreon   (United States)

Author keywords

Formulation development; Influenza; Plant derived; Recombinant hemagglutinin; Vaccine

Indexed keywords

ALPHA CYCLODEXTRIN; ALUMINUM; ALUMINUM HYDROXIDE; ASPARTIC ACID; BETA CYCLODEXTRIN; EXCIPIENT; GAMMA CYCLODEXTRIN; GLUCOSE; GLUTAMIC ACID; GLYCEROL; IMIDAZOLE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; LACTIC ACID; LACTOSE; LYSINE; MEMBRANE PROTEIN; POLIDOCANOL; POLOXAMER; POLYSORBATE 20; POLYSORBATE 80; RECOMBINANT ANTIGEN; RECOMBINANT PROTEIN; SODIUM CHLORIDE; SORBITOL; STABILIZING AGENT; SUCROSE; TREHALOSE; UNINDEXED DRUG; VIRUS VECTOR; IMMUNOLOGICAL ADJUVANT; RECOMBINANT VACCINE; SUBUNIT VACCINE; VIRUS ANTIBODY;

ADSORPTION; ANIMAL EXPERIMENT; ANTIBODY TITER; ANTIGEN PURIFICATION; ARTICLE; CENTRIFUGATION; CONTROLLED STUDY; DATA ANALYSIS; DRUG FORMULATION; FLUORESCENCE SPECTROSCOPY; GENE EXPRESSION SYSTEM; HEMAGGLUTINATION; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION CONTROL; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; LIGHT SCATTERING; MOUSE; NICOTIANA BENTHAMIANA; NONHUMAN; PH; PLANT VIRUS; PREVALENCE; PROTEIN STRUCTURE; SPECTROSCOPY; TEMPERATURE; THERMOSTABILITY; VIRUS STRAIN; ANIMAL; BLOOD; CHEMISTRY; GENE VECTOR; GENETICS; IMMUNOLOGY; PROTEIN STABILITY; TOBACCO;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, VIRAL; CHEMISTRY, PHARMACEUTICAL; EXCIPIENTS; GENETIC VECTORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HYDROGEN-ION CONCENTRATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MICE; PLANT VIRUSES; PROTEIN STABILITY; RECOMBINANT PROTEINS; SPECTRUM ANALYSIS; TEMPERATURE; TOBACCO; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84860776084     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.19106     Document Type: Article

References (38)

1. Plotkin SAOW. Vaccines 2004; 4.
2. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003; 21:1776-9; PMID:12686093; http://dx.doi.org/10.1016/S0264-410X(03)00071-9.
3. Sheridan C. Next generation flu vaccine boosted by Chiron debacle. Nat Biotechnol 2004; 22:1487-8; PMID:15583640; http://dx.doi.org/10.1038/nbt1204- 487.
4. Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 2004; 4:499-509; PMID:15288823; http://dx.doi.org/10.1016/S1473- 3099(04)01105-3.
5. Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox MM. Expression and purification of an influenza hemagglutinin - one step closer to a recombinant protein-based influenza vaccine. Vaccine 2006; 24:2176-85; PMID:16310896; http://dx.doi.org/10.1016/j.vaccine.2005.11.005.
6. Delaney JW, Fowler RA. 2009 influenza A (H1N1): a clinical review. Hosp Pract (Minneap) 2010; 38:74-81; PMID:20469616.
7. Maritz J, Maree L, Preiser W. Pandemic influenza A (H1N1) 2009: the experience of the first six months. Clin Chem Lab Med 2010; 48:11-21; PMID:20025556; http://dx.doi.org/10.1515/CCLM.2010.023.
8. Cox MM, Hollister JR. FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals 2009; 37:182-9; PMID:19297194; http://dx.doi.org/10.1016/j.biologicals.2009.02.014.
9. Cox MM, Patriarca PA, Treanor J. FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respi Viruses 2008; 2:211-9; PMID:19453397; http://dx.doi.org/10.1111/j.1750-2659.2008.00053.x.
10. Kissmann J, Joshi SB, Haynes JR, Dokken L, Richardson C, Middaugh CR. H1N1 influenza viruslike particles: physical degradation pathways and identification of stabilizers. J Pharm Sci 2011; 100:634-45; PMID:20669328; http://dx.doi.org/10.1002/jps.22304.
11. McPherson CE. Development of a novel recombinant influenza vaccine in insect cells. Biologicals 2008; 36:350-3; PMID:18804387; http://dx.doi.org/10. 1016/j.biologicals.2008.08.001.
12. Robertson JS, Naeve CW, Webster RG, Bootman JS, Newman R, Schild GC. Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology 1985; 143:166-74; PMID:4060580; http://dx.doi.org/10.1016/0042-6822(85)90105-9.
13. Schild GC, Oxford JS, de Jong JC, Webster RG. Evidence for host-cell selection of influenza virus antigenic variants. Nature 1983; 303:706-9; PMID:6190093; http://dx.doi.org/10.1038/303706a0.
14. Yusibov V, Streatfield SJ, Kushnir N. Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond. Hum Vaccin 2011; 7:313-21; PMID:21346417; http://dx.doi.org/10.4161/hv.7.3.14207.
15. Musiychuk K, Stephenson N, Bi H, Farrance CE, Orozovic G, Brodelius M, et al. A launch vector for the production of vaccine antigens in plants. Influenza Other Respi Viruses 2007; 1:19-25; PMID:19453476; http://dx.doi.org/10.1111/j. 1750-2659.2006.00005.x.
16. Perez-Iratxeta C, Andrade-Navarro MA. K2D2: estimation of protein secondary structure from circular dichroism spectra. BMC Struct Biol 2008; 8:25; PMID:18477405; http://dx.doi.org/10.1186/1472-6807-8-25.
17. Lin T, Wang G, Li A, Zhang Q, Wu C, Zhang R, et al. The hemagglutinin structure of an avian H1N1 influenza A virus. Virology 2009; 392:73-81; PMID:19628241; http://dx.doi.org/10.1016/j.virol.2009.06.028.
18. Cross KJ, Langley WA, Russell RJ, Skehel JJ, Steinhauer DA. Composition and functions of the influenza fusion peptide. Protein Pept Lett 2009; 16:766-78; PMID:19601906; http://dx.doi.org/10.2174/092986609788681715.
19. Harrison SC. Mechanism of membrane fusion by viral envelope proteins. Adv Virus Res 2005; 64:231-61; PMID:16139596; http://dx.doi.org/10.1016/S0065- 3527(05)64007-9.
20. Harrison SC. Viral membrane fusion. Nat Struct Mol Biol 2008; 15:690-8; PMID:18596815; http://dx.doi.org/10.1038/nsmb.1456.
21. Shimizu S, Smith DJ. Preferential hydration and the exclusion of cosolvents from protein surfaces. J Chem Phys 2004; 121:1148-54; PMID:15260652; http://dx.doi.org/10.1063/1.1759615.
22. Uedaira H, Uedaira H. Role of hydration of polyhydroxy compounds in biological systems. Cell Mol Biol (Noisy-le-grand) 2001; 47:823-9; PMID:11728096.
23. Lee JC, Timasheff SN. The stabilization of proteins by sucrose. J Biol Chem 1981; 256:7193-201; PMID:7251592.
24. Edelman R, Wasserman SS, Kublin JG, Bodison SA, Nardin EH, Oliveira GA, et al. Immediate-type hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites. Vaccine 2002; 21:269-80; PMID:12450702; http://dx.doi.org/10.1016/S0264-410X(02)00468-1.
25. Keitel WA, Kester KE, Atmar RL, White AC, Bond NH, Holland CA, et al. Phase I trial of two recombinant vaccines containing the 19 kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine 1999; 18:531-9; PMID:10519944; http://dx.doi.org/10.1016/S0264-410X(99)00221-2.
26. Kaslow DC. Transmission-blocking vaccines. Chem Immunol 2002; 80:287-307; PMID:12058646; http://dx.doi.org/10.1159/000058850.
27. Glenny AT, Buttle GAH, Stevens MF. Rate of disappearance of diphtheria toxoid injected into rabbits and guinea-pigs: Toxoid precipitated with alum. J Pathol Bacteriol 1931; 34:267-75; http://dx.doi.org/10.1002/path.1700340214.
28. McKee AS, Munks MW, MacLeod MK, Fleenor CJ, Van Rooijen N, Kappler JW, et al. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 2009; 183:4403-14; PMID:19734227; http://dx.doi.org/10.4049/jimmunol.0900164.
29. Flach TL, Ng G, Hari A, Desrosiers MD, Zhang P, Ward SM, et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med 2011; 17:479-87; PMID:21399646; http://dx.doi.org/10. 1038/nm.2306.
30. Noe SM, Green MA, HogenEsch H, Hem SL. Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response. Vaccine 2010; 28:3588-94; PMID:20211692; http://dx.doi.org/10.1016/j.vaccine.2010.02.085.
31. Jones LS, Peek LJ, Power J, Markham A, Yazzie B, Middaugh CR. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J Biol Chem 2005; 280:13406-14; PMID:15684430; http://dx.doi.org/10.1074/jbc.M500687200.
32. Peek LJ, Martin TT, Elk Nation C, Pegram SA, Middaugh CR. Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants. J Pharm Sci 2007; 96:547-57; PMID:17080408; http://dx.doi.org/10. 1002/jps.20762.
33. FDA. USCFR - Code of Federal Regulations Title 21. [cited 2011 December 9]; Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/ CFRSearch.cfm?fr=610.15.
34. Shoji Y, Chichester JA, Jones M, Manceva SD, Damon E, Mett V, et al. Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza. Hum Vaccin 2011; 7:41-50; PMID:21266846; http://dx.doi.org/10.4161/hv.7.0.14561.
35. Fan H, Ralston J, Dibiase M, Faulkner E, Middaugh CR. Solution behavior of IFNbeta-1a: an empirical phase diagram based approach. J Pharm Sci 2005; 94:1893-911; PMID:16052555; http://dx.doi.org/10.1002/jps.20410.
36. Kueltzo LA, Ersoy B, Ralston JP, Middaugh CR. Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: a bGCSF case study. J Pharm Sci 2003; 92:1805-20; PMID:12949999; http://dx.doi.org/10.1002/jps.10439.
37. Maddux NR, Joshi SB, Volkin DB, Ralston JP, Middaugh CR. Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J Pharm Sci 2011; PMID:21647886; http://dx.doi.org/10.1002/jps.22618.
38. Shoji Y, Chichester JA, Bi H, Musiychuk K, de la Rosa P, Goldschmidt L, et al. Plant-expressed HA as a seasonal influenza vaccine candidate. Vaccine 2008; 26:2930-4; PMID:18440103; http://dx.doi.org/10.1016/j.vaccine.2008.03.045.